Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases

Journal of Controlled Release

Volumn 157, Issue 3, 2012, Pages 461-468

  Dolman, M E M ^a   Van Dorenmalen, K M A ^a   Pieters, E H E ^a   Lacombe, M ^b   Pato, J ^c   Storm, G ^a   Hennink, W E ^a   Kok, R J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Kreatech Biotechnology BV   (Netherlands)

^c Vichem Chemie Ltd   (Hungary)

Author keywords

Drug delivery; Imatinib; Kidney; Lysozyme; Platinum linker; UUO

Indexed keywords

ANIMAL MODEL; ANTICANCER DRUG; ANTIFIBROTIC EFFECT; FIBROTIC DISEASE; IMATINIB; IMATINIB MESYLATE; INTRAPERITONEAL ADMINISTRATION; INTRAPERITONEALLY; KIDNEY; LOW MOLECULAR WEIGHT; LYSOZYME; MATRIX; PLATELET-DERIVED GROWTH FACTOR RECEPTORS; PROTEIN LYSOZYME; RENAL DISEASE; SIDE EFFECT; TUBULAR CELLS; UUO;

BIOCHEMISTRY; CYTOLOGY; DISEASES; DRUG DELIVERY; PLATINUM;

ENZYMES;

IMATINIB; LYSOZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBULOINTERSTITIAL FIBROSIS; URETER OBSTRUCTION;

ANIMALS; CELL LINE; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; MURAMIDASE; MYOCARDIUM; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84856682537     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.08.041     Document Type: Article

References (51)

1. L.O. Lerman, and A.R. Chade Angiogenesis in the kidney: a new therapeutic target? Curr. Opin. Nephrol. Hypertens. 18 2009 160 165
2. P. Boor, T. Ostendorf, and J. Floege Renal fibrosis: novel insights into mechanisms and therapeutic targets Nat. Rev. Nephrol. 6 2010 643 656
3. Y. Liu Renal fibrosis: new insights into the pathogenesis and therapeutics Kidney Int. 69 2006 213 217 (Pubitemid 43323069)
4. M. Zeisberg, and E.G. Neilson Mechanisms of tubulointerstitial fibrosis J. Am. Soc. Nephrol. 21 2010 1819 1834
5. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J. Pharmacol. Exp. Ther. 315 2005 971 979 (Pubitemid 41635382)
6. S.K. Grant Therapeutic protein kinase inhibitors Cell. Mol. Life Sci. 66 2009 1163 1177
7. J. Rosenbloom, S.V. Castro, and S.A. Jimenez Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies Ann. Intern. Med. 152 2010 159 166
8. A. Abdollahi, M. Li, G. Ping, C. Plathow, S. Domhan, F. Kiessling, L.B. Lee, G. McMahon, H.J. Grone, K.E. Lipson, and P.E. Huber Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J. Exp. Med. 201 2005 925 935 (Pubitemid 40524462)
9. A. Akhmetshina, P. Venalis, C. Dees, N. Busch, J. Zwerina, G. Schett, O. Distler, and J.H. Distler Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum. 60 2009 219 224
10. C.E. Daniels, M.C. Wilkes, M. Edens, T.J. Kottom, S.J. Murphy, A.H. Limper, and E.B. Leof Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J. Clin. Invest. 114 2004 1308 1316 (Pubitemid 40385302)
11. S. Wang, M.C. Wilkes, E.B. Leof, and R. Hirschberg Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis Am. J. Physiol. Renal Physiol. 298 2010 F142 F149
12. H. Yoshiji, R. Noguchi, S. Kuriyama, Y. Ikenaka, J. Yoshii, K. Yanase, T. Namisaki, M. Kitade, T. Masaki, and H. Fukui Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats Am. J. Physiol. Gastrointest. Liver Physiol. 288 2005 G907 G913
13. M.L. Hensley, and J.M. Ford Imatinib treatment: specific issues related to safety, fertility, and pregnancy Semin. Hematol. 40 2003 21 25
14. P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant. 22 2007 3391 3407 (Pubitemid 350212482)
15. E.P. Bottinger, and M. Bitzer TGF-beta signaling in renal disease J. Am. Soc. Nephrol. 13 2002 2600 2610
16. J. Floege, F. Eitner, and C.E. Alpers A new look at platelet-derived growth factor in renal disease J. Am. Soc. Nephrol. 19 2008 12 23
17. W.W. Tang, T.R. Ulich, D.L. Lacey, D.C. Hill, M. Qi, S.A. Kaufman, G.Y. Van, J.E. Tarpley, and J.S. Yee Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis Am. J. Pathol. 148 1996 1169 1180 (Pubitemid 26108254)
18. S. Wang, M.C. Wilkes, E.B. Leof, and R. Hirschberg Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo FASEB J. 19 2005 1 11 (Pubitemid 40069914)
19. Y. Aono, Y. Nishioka, M. Inayama, M. Ugai, J. Kishi, H. Uehara, K. Izumi, and S. Sone Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice Am. J. Respir. Crit. Care Med. 171 2005 1279 1285 (Pubitemid 40740736)
20. M. Baumann, K. Leineweber, M. Tewiele, K. Wu, T.R. Turk, S. Su, M. Gossl, T. Buck, B. Wilde, U. Heemann, A. Kribben, and O. Witzke Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function Nephrol. Dial. Transplant. 25 2010 1817 1824
21. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am. J. Respir. Crit. Care Med. 181 2010 604 610
22. J.H. Distler, and O. Distler Imatinib as a novel therapeutic approach for fibrotic disorders Rheumatology (Oxford) 48 2009 2 4
23. M. Neef, M. Ledermann, H. Saegesser, V. Schneider, N. Widmer, L.A. Decosterd, B. Rochat, and J. Reichen Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term J. Hepatol. 44 2006 167 175 (Pubitemid 41772531)
24. R. Vittal, H. Zhang, M.K. Han, B.B. Moore, J.C. Horowitz, and V.J. Thannickal Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases J. Pharmacol. Exp. Ther. 321 2007 35 44 (Pubitemid 46456971)
25. E.I. Christensen, and H. Birn Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule Am. J. Physiol. Renal Physiol. 280 2001 F562 F573
26. E.I. Christensen, P.J. Verroust, and R. Nielsen Receptor-mediated endocytosis in renal proximal tubule Pflugers Arch. 458 2009 1039 1048
27. M.E.M. Dolman, S. Harmsen, G. Storm, W.E. Hennink, and R.J. Kok Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells Adv. Drug Deliv. Rev. 14 2010 1344 1357
28. R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, F.J. Clubb, A. Rosenzweig, R.N. Salomon, R.A. Van Etten, J. Alroy, J.B. Durand, and T. Force Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat. Med. 12 2006 908 916 (Pubitemid 44175142)
29. J. Prakash, M.H. de Borst, M. Lacombe, F. Opdam, P.A. Klok, H. van Goor, D.K. Meijer, F. Moolenaar, K. Poelstra, and R.J. Kok Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury J. Am. Soc. Nephrol. 19 2008 2086 2097
30. J. Prakash, M.H. de Borst, A.M. van Loenen-Weemaes, M. Lacombe, F. Opdam, H. van Goor, D.K. Meijer, F. Moolenaar, K. Poelstra, and R.J. Kok Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis Pharm. Res. 25 2008 2427 2439
31. J. Prakash, M. Sandovici, V. Saluja, M. Lacombe, R.Q. Schaapveld, M.H. de Borst, H. van Goor, R.H. Henning, J.H. Proost, F. Moolenaar, G. Keri, D.K. Meijer, K. Poelstra, and R.J. Kok Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4- hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis J. Pharmacol. Exp. Ther. 319 2006 8 19 (Pubitemid 44455106)
32. T. Gonzalo, E.G. Talman, A. van de Ven, K. Temming, R. Greupink, L. Beljaars, C. Reker-Smit, D.K. Meijer, G. Molema, K. Poelstra, and R.J. Kok Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology J. Control. Release 111 2006 193 203 (Pubitemid 43290008)
33. M.M. Fretz, M.E.M. Dolman, M. Lacombe, J. Prakash, T.Q. Nguyen, R. Goldschmeding, J. Pato, G. Storm, W.E. Hennink, and R.J. Kok Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors J. Control. Release 132 2008 200 207
34. K.T. Papazisis, G.D. Geromichalos, K.A. Dimitriadis, and A.H. Kortsaris Optimization of the sulforhodamine B colorimetric assay J. Immunol. Methods 208 1997 151 158 (Pubitemid 28015342)
35. R.L. Oostendorp, J.H. Beijnen, J.H. Schellens, and O. Tellingen Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography Biomed. Chromatogr. 21 2007 747 754 (Pubitemid 47082252)
36. K. Temming, M. Lacombe, R.Q. Schaapveld, L. Orfi, G. Keri, K. Poelstra, G. Molema, and R.J. Kok Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium ChemMedChem 1 2006 1200 1203 (Pubitemid 44786926)
37. S. Harmsen, M.E.M. Dolman, Z. Nemes, M. Lacombe, B. Szokol, J. Pato, G. Keri, L. Orfi, G. Storm, W.E. Hennink, and R.J. Kok Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate Bioconjug. Chem. 22 2011 540 545
38. J.G. Kiselar, S.D. Maleknia, M. Sullivan, K.M. Downard, and M.R. Chance Hydroxyl radical probe of protein surfaces using synchrotron X-ray radiolysis and mass spectrometry Int. J. Radiat. Biol. 78 2002 101 114 (Pubitemid 34098342)
39. C. Lebeau, F.D. Debelle, V.M. Arlt, A. Pozdzik, E.G. De Prez, D.H. Phillips, M.M. Deschodt-Lanckman, J.L. Vanherweghem, and J.L. Nortier Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies Nephrol. Dial. Transplant. 20 2005 2321 2332 (Pubitemid 41548855)
40. E.I. Christensen, and H. Birn Megalin and cubilin: multifunctional endocytic receptors Nat. Rev. Mol. Cell Biol. 3 2002 256 266 (Pubitemid 34619261)
41. P.J. Verroust, H. Birn, R. Nielsen, R. Kozyraki, and E.I. Christensen The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology Kidney Int. 62 2002 745 756 (Pubitemid 35316702)
42. J.R. Leheste, B. Rolinski, H. Vorum, J. Hilpert, A. Nykjaer, C. Jacobsen, P. Aucouturier, J.O. Moskaug, A. Otto, E.I. Christensen, and T.E. Willnow Megalin knockout mice as an animal model of low molecular weight proteinuria Am. J. Pathol. 155 1999 1361 1370 (Pubitemid 29488943)
43. D.G. Struijk, R.T. Krediet, G.C. Koomen, E.W. Boeschoten, H.J. vd Reijden, and L. Arisz Indirect measurement of lymphatic absorption with inulin in continuous ambulatory peritoneal dialysis (CAPD) patients Perit. Dial. Int. 10 1990 141 145 (Pubitemid 20173883)
44. A. Rippe, C. Rippe, K. Sward, and B. Rippe Disproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysis Nephrol. Dial. Transplant. 22 2007 88 95 (Pubitemid 46050332)
45. S. Mahboobi, A. Sellmer, A. Eswayah, S. Elz, A. Uecker, and F.D. Bohmer Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole Eur. J. Med. Chem. 43 2008 1444 1453 (Pubitemid 351885215)
46. E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, and J.D. Griffin AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br. J. Cancer 94 2006 1765 1769 (Pubitemid 43882564)
47. M.A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D.E. Shaw, N.P. Shah, J. Kuriyan, and D.J. Maly Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res. 69 2009 2384 2392
48. M. Kimura, M. Asano, K. Abe, M. Miyazaki, T. Suzuki, and A. Hishida Role of atrophic changes in proximal tubular cells in the peritubular deposition of type IV collagen in a rat renal ablation model Nephrol. Dial. Transplant. 20 2005 1559 1565 (Pubitemid 41418577)
49. H.Y. Lan Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells Curr. Opin. Nephrol. Hypertens. 12 2003 25 29 (Pubitemid 36092311)
50. F. Strutz, and G.A. Muller Renal fibrosis and the origin of the renal fibroblast Nephrol. Dial. Transplant. 21 2006 3368 3370 (Pubitemid 44817082)
51. Y. Liu Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention J. Am. Soc. Nephrol. 15 2004 1 12 (Pubitemid 38020692)